The study looked at Merck & Co’s Keytruda as a first-line treatment for gastric cancer, and prompted questions about the meaningfulness of non-inferiority.
Kantar’s Debbie Warner and Michael Gaschler debate the results in the video below.
The study looked at Merck & Co’s Keytruda as a first-line treatment for gastric cancer, and prompted questions about the meaningfulness of non-inferiority.
Kantar’s Debbie Warner and Michael Gaschler debate the results in the video below.
Publications